SRPT logo

Sarepta Therapeutics, Inc.

SRPT
Healthcare|Biotechnology|US
$17.82
+0.25 (+1.42%)
Tangible Book / Share
$14.15
Graham Number
$6.73
Cash / Share
$8.30
Next Earnings Report
Feb 24, 2027
EPS est. -$0.06 · Revenue est. $351.4M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (7)

Nov 2026
Est. completion
Spinal Muscular Atrophy
Early Check: Expanded Screening in Newborns
NCT03655223n=30,000
May 2027
Est. completion
P3Duchenne Muscular Dystrophy
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
Aug 2027
Est. completion
P4Duchenne Muscular Dystrophy
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
Nov 2027
Est. completion
P1Huntington's Disease
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Dec 2027
Est. completion
P1Duchenne Muscular Dystrophy
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Aug 2028
Est. completion
P1Limb Girdle Muscular Dystrophy
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
Sep 2030
Est. completion
Limb-girdle Muscular Dystrophy
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
P3
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430
Mar 2026
P2
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564
Mar 2025
P3
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513

Recent Press Releases

SEC Filings (64)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 20268-KMaterial eventDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Sep 23, 20268-KMaterial eventDocumentIndex
Aug 14, 202613F-HRInstitutional holdings reportDocumentIndex
Aug 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Jul 31, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 30, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 28, 2026S-8Employee stock planDocumentIndex
Jul 27, 20268-KMaterial eventDocumentIndex
Jun 4, 2026S-8Employee stock planDocumentIndex
Jun 4, 20268-KMaterial eventDocumentIndex
May 13, 202613F-HRInstitutional holdings reportDocumentIndex
May 6, 20268-KMaterial eventDocumentIndex
May 6, 202610-QQuarterly reportDocumentIndex
Apr 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 24, 2026ARSAnnual report to holdersDocumentIndex
Apr 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 2, 202610-KAnnual reportDocumentIndex
Feb 25, 20268-KMaterial eventDocumentIndex
Feb 25, 20268-KMaterial eventDocumentIndex
Feb 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 13, 202613F-HRInstitutional holdings reportDocumentIndex
Jan 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 19, 20258-KMaterial eventDocumentIndex
Dec 11, 20258-KMaterial eventDocumentIndex
Dec 8, 20258-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 10, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 6, 202510-QQuarterly reportDocumentIndex
Nov 3, 20258-KMaterial eventDocumentIndex
Sep 8, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 29, 20258-KMaterial eventDocumentIndex
Aug 21, 20258-KMaterial eventDocumentIndex